(BEAM) Beam Therapeutics - Ratings and Ratios
Base Editing Platform
BEAM EPS (Earnings per Share)
BEAM Revenue
Description: BEAM Beam Therapeutics
Beam Therapeutics Inc (NASDAQ:BEAM) is a biotechnology company focused on developing gene editing therapies. As a US-based company in the biotechnology sub-industry, BEAMs stock performance is closely tied to advancements in its gene editing technology and the overall sentiment towards the biotech sector.
The companys market capitalization stands at approximately $1.98 billion, indicating a moderate level of market presence. The absence of a Price-to-Earnings (P/E) ratio, both current and forward, suggests that BEAM is not yet profitable, a common characteristic among companies in the biotechnology industry that are often in the development phase. The Return on Equity (RoE) is negative at -44.24%, further indicating that the company is currently operating at a loss.
Key economic drivers for BEAM include the progress of its gene editing pipeline, partnerships or collaborations with other biotech or pharmaceutical companies, and the overall regulatory environment for gene therapies. Investors should monitor clinical trial results, FDA approvals, and any strategic alliances that could impact the companys financials and stock performance.
From a trading perspective, BEAMs stock has shown volatility, with a beta of 2.077 indicating that it is more than twice as volatile as the overall market. This suggests that the stock could be risky but also potentially rewarding for traders willing to take on that risk. Average trading volume is around 2.16 million shares, providing a reasonable level of liquidity.
To evaluate BEAMs potential, investors should focus on key performance indicators (KPIs) such as cash runway, research and development (R&D) expenses as a percentage of total expenses, and the number of ongoing clinical trials. Additionally, news on partnerships, regulatory milestones, and advancements in gene editing technology will be crucial. The companys ability to secure funding, either through equity offerings or partnerships, will also be a critical factor in its ability to continue operations and advance its pipeline.
BEAM Stock Overview
| Market Cap in USD | 1,655m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2020-02-06 |
BEAM Stock Ratings
| Growth Rating | -71.8% |
| Fundamental | 22.8% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -24.7% |
| Analyst Rating | 4.41 of 5 |
BEAM Dividends
Currently no dividends paidBEAM Growth Ratios
| Growth Correlation 3m | 0.7% |
| Growth Correlation 12m | -67.9% |
| Growth Correlation 5y | -85% |
| CAGR 5y | -24.82% |
| CAGR/Max DD 3y | -0.34 |
| CAGR/Mean DD 3y | -0.49 |
| Sharpe Ratio 12m | -0.97 |
| Alpha | 0.08 |
| Beta | 0.888 |
| Volatility | 85.82% |
| Current Volume | 3251.9k |
| Average Volume 20d | 2444.9k |
| Stop Loss | 21.6 (-5.7%) |
| Signal | 1.76 |
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income (-398.6m TTM) > 0 and > 6% of Revenue (6% = 3.62m TTM) |
| FCFTA -0.26 (>2.0%) and ΔFCFTA -11.10pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 1661 % (prev 241.7%; Δ 1420 pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.25 (>3.0%) and CFO -344.8m > Net Income -398.6m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 6.75 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (102.0m) change vs 12m ago 23.91% (target <= -2.0% for YES) |
| Gross Margin 72.70% (prev 93.24%; Δ -20.54pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 4.54% (prev 27.95%; Δ -23.41pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -17.11 (EBITDA TTM -396.5m / Interest Expense TTM 24.5m) >= 6 (WARN >= 3) |
Altman Z'' -6.98
| (A) 0.72 = (Total Current Assets 1.18b - Total Current Liabilities 174.1m) / Total Assets 1.39b |
| (B) -1.28 = Retained Earnings (Balance) -1.78b / Total Assets 1.39b |
| warn (B) unusual magnitude: -1.28 — check mapping/units |
| (C) -0.32 = EBIT TTM -418.4m / Avg Total Assets 1.33b |
| (D) -5.16 = Book Value of Equity -1.78b / Total Liabilities 344.3m |
| Total Rating: -6.98 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 22.80
| 1. Piotroski 0.0pt = -5.0 |
| 2. FCF Yield -51.78% = -5.0 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.17 = 2.48 |
| 5. Debt/Ebitda -0.46 = -2.50 |
| 6. ROIC - WACC (= -54.20)% = -12.50 |
| 7. RoE -43.15% = -2.50 |
| 8. Rev. Trend -26.33% = -1.97 |
| 9. EPS Trend -4.22% = -0.21 |
What is the price of BEAM shares?
Over the past week, the price has changed by +12.50%, over one month by +33.98%, over three months by +37.85% and over the past year by -10.58%.
Is Beam Therapeutics a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of BEAM is around 16.74 USD . This means that BEAM is currently overvalued and has a potential downside of -26.93%.
Is BEAM a buy, sell or hold?
- Strong Buy: 10
- Buy: 4
- Hold: 3
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the BEAM price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 45.9 | 100.4% |
| Analysts Target Price | 45.9 | 100.4% |
| ValueRay Target Price | 18.7 | -18.2% |
Last update: 2025-09-03 04:32
BEAM Fundamental Data Overview
CCE Cash And Equivalents = 1.15b USD (Cash And Short Term Investments, last quarter)
P/S = 27.459
P/B = 1.581
Beta = 2.225
Revenue TTM = 60.3m USD
EBIT TTM = -418.4m USD
EBITDA TTM = -396.5m USD
Long Term Debt = 170.2m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 12.9m USD (from shortTermDebt, last quarter)
Debt = 183.2m USD (Calculated: Short Term 12.9m + Long Term 170.2m)
Net Debt = -127.3m USD (from netDebt column, last quarter)
Enterprise Value = 687.8m USD (1.66b + Debt 183.2m - CCE 1.15b)
Interest Coverage Ratio = -17.11 (Ebit TTM -418.4m / Interest Expense TTM 24.5m)
FCF Yield = -51.78% (FCF TTM -356.2m / Enterprise Value 687.8m)
FCF Margin = -591.0% (FCF TTM -356.2m / Revenue TTM 60.3m)
Net Margin = -661.3% (Net Income TTM -398.6m / Revenue TTM 60.3m)
Gross Margin = 72.70% ((Revenue TTM 60.3m - Cost of Revenue TTM 16.5m) / Revenue TTM)
Tobins Q-Ratio = -0.39 (set to none) (Enterprise Value 687.8m / Book Value Of Equity -1.78b)
Interest Expense / Debt = 6.73% (Interest Expense 12.3m / Debt 183.2m)
Taxrate = 21.0% (US default)
NOPAT = -418.4m (EBIT -418.4m, no tax applied on loss)
Current Ratio = 6.75 (Total Current Assets 1.18b / Total Current Liabilities 174.1m)
Debt / Equity = 0.17 (Debt 183.2m / last Quarter total Stockholder Equity 1.05b)
Debt / EBITDA = -0.46 (Net Debt -127.3m / EBITDA -396.5m)
Debt / FCF = -0.51 (Debt 183.2m / FCF TTM -356.2m)
Total Stockholder Equity = 923.7m (last 4 quarters mean)
RoA = -28.65% (Net Income -398.6m, Total Assets 1.39b )
RoE = -43.15% (Net Income TTM -398.6m / Total Stockholder Equity 923.7m)
RoCE = -38.25% (Ebit -418.4m / (Equity 923.7m + L.T.Debt 170.2m))
RoIC = -45.30% (NOPAT -418.4m / Invested Capital 923.7m)
WACC = 8.89% (E(1.66b)/V(1.84b) * Re(9.29%)) + (D(183.2m)/V(1.84b) * Rd(6.73%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 90.91 | Cagr: 3.44%
Discount Rate = 9.29% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -356.2m)
EPS Correlation: -4.22 | EPS CAGR: 88.38% | SUE: 0.12 | # QB: 0
Revenue Correlation: -26.33 | Revenue CAGR: -20.30% | SUE: N/A | # QB: None
Additional Sources for BEAM Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle